IMC-001

· ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for IMC-001, covering 2026-04-15 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type [Phase 2]